Amendments to the Claims under Revised 37 C.F.R. § 1.121

Claim 1 (currently amended): A reagent for detecting human papilloma virus (HPV) DNA in a cell sample which indicates the patient providing the cell sample is at risk for cancer comprising a plurality of viral genomic HPV DNA probe[[s]] sets, wherein each probe set comprises a plurality of nucleic acid molecules that detectably hybridize to DNA from a plurality of carcinogenic HPV types but do not detectably hybridize to DNA from non carcinogenic HPV types substantially all of the full-length genomic sequence of HPV types 16, 18, 31, 33, 35, or 51.

Claim 2 (cancelled).

Claim 3 (currently amended): The reagent of claim 2-1, wherein the viral-genomic HPV DNA probes also hybridize to substantially all of the full-length genomic sequence of HPV types 39, 45, 52, 56, 58, 59, 68 and 70.

Claims 4-6 (cancelled).

Claim 7 (currently amended): The reagent of claim 61, wherein the viral genomic HPV DNA probes are present in the reagent in the following proportions: HPV 16 - 8.3%, HPV 18 - 20.8%, HPV 31 - 8.3%, HPV 33 - 20.8%, HPV 35 - 20.8%, and HPV 51 - 20.8%.

Claim 8-16 (cancelled).

Claim 17 (currently amended): A kit for detecting high and intermediate risk human papilloma virus DNA in a sample comprising a container containing the reagent of claim 1.

Claim 18 (cancelled).

Claim 19 (currently amended):

A kit for detecting high and intermediate risk-human papilloma

virus DNA in a sample comprising a container containing the reagent of claim 3.

Claims 20-21 (cancelled).

Claim 22 (currently amended): A kit for detecting high and intermediate risk human papilloma virus DNA in a sample comprising a container containing the reagent of claim 7.